PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
21424914-11	2011	In the rosiglitazone group, FPG, PPG, HbA1c, insulin, HOMA-IR, IL-6, and TNF-alpha levels decreased significantly after 12 weeks compared with the basal levels.	Rosiglitazone	7-20	interleukin 6	Homo sapiens	54-67	
19673614-10	2009	Also, the patients who received rosiglitazone had reduced inflammatory responses to infection, compared with the patients who received a placebo (ie, interleukin-6 levels at 24 h [p < .005] and at 48 h [p = .013] and monocyte chemoattractant protein-1 level at 48 h [p = .05]).	Rosiglitazone	32-45	interleukin 6	Homo sapiens	150-163	
21031343-0	2011	Effects of rosiglitazone/metformin fixed-dose combination therapy and metformin monotherapy on serum vaspin, adiponectin and IL-6 levels in drug-naive patients with type 2 diabetes.	Rosiglitazone	11-24	interleukin 6	Homo sapiens	125-129	
21031343-7	2011	There was a considerable amelioration of hsCRP, WBC, adiponectin, IL-6, systolic and diastolic BP with rosiglitazone/metformin combined treatment as compared to baseline (p < 0.05) and MET group (p < 0.05).	Rosiglitazone	103-116	interleukin 6	Homo sapiens	66-70	
21031343-12	2011	CONCLUSIONS: Both rosiglitazone/metformin combination therapy and metformin monotherapy decreased serum vaspin levels through glucose and insulin sensitivity regulation, while they exerted differential effects on adiponectin, IL-6 and other cardiovascular risk factors in drug-naive patients with T2DM.	Rosiglitazone	18-31	interleukin 6	Homo sapiens	226-230	
20921996-0	2010	Rosiglitazone regulates IL-6-stimulated lipolysis in porcine adipocytes.	Rosiglitazone	0-13	interleukin 6	Homo sapiens	24-28	
20921996-2	2010	However, the effects of the anti-diabetic drug rosiglitazone on IL-6-stimulated lipolysis and the underlying molecular mechanism are largely unknown.	Rosiglitazone	47-60	interleukin 6	Homo sapiens	64-68	
20921996-3	2010	In this study, we demonstrated that rosiglitazone suppressed IL-6-stimulated lipolysis in differentiated porcine adipocytes by inactivation of extracellular signal-related kinase (ERK).	Rosiglitazone	36-49	interleukin 6	Homo sapiens	61-65	
20921996-5	2010	In addition, rosiglitazone significantly reversed IL-6-induced down-regulation of several genes such as perilipin A, peroxisome proliferators activated receptor gamma (PPARγ), and fatty acid synthetase, as well as the up-regulation of IL-6 mRNA.	Rosiglitazone	13-26	interleukin 6	Homo sapiens	50-54	
20921996-5	2010	In addition, rosiglitazone significantly reversed IL-6-induced down-regulation of several genes such as perilipin A, peroxisome proliferators activated receptor gamma (PPARγ), and fatty acid synthetase, as well as the up-regulation of IL-6 mRNA.	Rosiglitazone	13-26	interleukin 6	Homo sapiens	245-249	
20921996-6	2010	However, mRNA expression of PPARγ coactivator-1 alpha (PCG-1α) was enhanced by rosiglitazone in IL-6-stimulated adipocytes.	Rosiglitazone	99-112	interleukin 6	Homo sapiens	116-120	
20921996-7	2010	These results indicate that rosiglitazone suppresses IL-6-stimulated lipolysis in porcine adipocytes through multiple molecular mechanisms.	Rosiglitazone	28-41	interleukin 6	Homo sapiens	53-57	
20003221-14	2009	The concentration of IL-6 following rosiglitazone exposure did not significantly decrease comparing to control.	Rosiglitazone	36-49	interleukin 6	Homo sapiens	21-25	
19782427-6	2009	The importance of ERK activation in mediating the synergism of the two cytokines is further confirmed by the inhibitory effect of the anti-diabetic drug rosiglitazone and ERK blockers on IP-10, MIG and IL-6 secretion.	Rosiglitazone	153-166	interleukin 6	Homo sapiens	202-206	
19923143-9	2010	The peroxisome proliferator-activated receptor-gamma (PPAR-gamma) agonist, rosiglitazone, attenuated HG-induced PKC but not HG- or BK- induced MAPK p42/44 activation and reduced HG-stimulated VEGF, along with IL-6, CCL-2 and TGF-beta secretion.	Rosiglitazone	75-88	interleukin 6	Homo sapiens	209-213	
19443277-5	2009	Dual treatment of rosiglitazone and losartan provided synergistic effect in reducing ICAM-1, IL-6 and ATR1 expression and NF-kappaB and ERK1/2 activation induced by the conditioned media when compared with monotherapy.	Rosiglitazone	18-31	interleukin 6	Homo sapiens	93-97	
18541328-8	2008	Plasma IL-6 (-25%), CRP (-55%) and GGT (-25%) concentrations declined significantly in the rosiglitazone group.	Rosiglitazone	91-104	interleukin 6	Homo sapiens	7-11	
19155534-9	2009	The PPAR-gamma antagonist, GW9662, significantly attenuated the inhibitory action of rosiglitazone on the increased synthesis of IL-6 and ATR1 protein.	Rosiglitazone	85-98	interleukin 6	Homo sapiens	129-133	
17141246-3	2007	The objectives of this study were to examine the influence of PPAR gamma and its agonist (rosiglitazone) on the TNFalpha, IL-6, IL-8 and IL-10 gene expression in monocytes of patients with diabetic macroangiopathy and to analyse obtained results in context of selected atherogenic factors ant direct indicators of endothelial lesion.	Rosiglitazone	90-103	interleukin 6	Homo sapiens	122-126	
18583261-5	2008	RESULTS: In group A, rosiglitazone treatment resulted in significantly reduced serum hs-CRP, IL-1beta, IL-6, TNF-alpha, FPG and insulin resistance index (P<0.01).	Rosiglitazone	21-34	interleukin 6	Homo sapiens	103-107	
17922475-9	2008	IL-6 production was stimulated by PMA in both C and T2D patients; this effect was prevented by rosiglitazone in a Sr202-inhibitable manner.	Rosiglitazone	95-108	interleukin 6	Homo sapiens	0-4	
15526907-6	2004	Importantly, PPARgamma agonists troglitazone, rosiglitazone, and 15-deoxy-delta(12, 14)-prosglandin J2 significantly decreased the up expression of TNF-alpha and IL-6 in HMCL supernatants stimulated by IL-1beta.	Rosiglitazone	46-59	interleukin 6	Homo sapiens	162-166	
17224000-11	2007	Significant decreases in resistin, C-reactive protein, TNF-alpha, IL-6 and IL-18 were seen in the rosiglitazone-treated patients but not in the metformin-treated patients.	Rosiglitazone	98-111	interleukin 6	Homo sapiens	66-70	
16137694-7	2006	Rosiglitazone reduced the incremental area under the curves (dAUCs) for IL-6 (-63%, p<0.01) and IL-8 (-16%, p<0.05).	Rosiglitazone	0-13	interleukin 6	Homo sapiens	72-76	
16137694-9	2006	CONCLUSIONS: Rosiglitazone attenuated the postprandial increases of neutrophils, IL-6 and IL-8 in patients with type 2 diabetes.	Rosiglitazone	13-26	interleukin 6	Homo sapiens	81-85	
16137694-12	2006	Rosiglitazone attenuated the postprandial increases of neutrophils, IL-6 and IL-8 in patients with type 2 diabetes.	Rosiglitazone	0-13	interleukin 6	Homo sapiens	68-72	
16223437-1	2005	The objective was to investigate the relationship between homocysteine (HCY), peroxisome proliferator-activated receptors (PPAR)-gamma and the expression of interleukin 6 (IL-6) and microsomal prostaglandin E synthase (mPGES) by peripheral blood mononuclear cell (PBMC) culture in vitro, as well as to look at the intervention with HCY and PPAR-gamma activators (troglitazone and rosiglitazone).	Rosiglitazone	380-393	interleukin 6	Homo sapiens	157-170	
14749206-5	2004	Twenty-four-week treatment with rosiglitazone (8 mg/day) compared with placebo significantly increased the expression of adiponectin, peroxisome proliferator-activated receptor-gamma (PPARgamma), and PPARgamma coactivator 1 and decreased IL-6 expression.	Rosiglitazone	32-45	interleukin 6	Homo sapiens	238-242	
12163427-4	2002	The purpose of this analysis was to determine whether rosiglitazone alters serum concentrations of CRP, IL-6, MMP-9, and white blood cell count (WBC) and to examine the relationship of these effects with demographic and disease variables.	Rosiglitazone	54-67	interleukin 6	Homo sapiens	104-108	
12509942-8	2002	PPARgamma agonists troglitazone, rosiglitazone, and 15-deoxy-Delta(12, 14)-prosglandin J(2) significantly decreased the upexpression of TNF-alpha and IL-6 in HMCL supernatants stimulated by IL-1beta.	Rosiglitazone	33-46	interleukin 6	Homo sapiens	150-154	
12163427-7	2002	The percentage reduction in mean IL-6 was small and similar in the rosiglitazone and placebo groups.	Rosiglitazone	67-80	interleukin 6	Homo sapiens	33-37	
34170488-4	2022	We aimed to study the effect of RGZ onto inflammation-induced secretion of CXCL10, IFNgamma, TNFalpha, interleukin (IL)-6 and IL-8 by human CD4 + T and DCs, and onto IFNgamma/TNFalpha-dependent signaling in human cardiomyocytes associated with chemokine release.	Rosiglitazone	32-35	interleukin 6	Homo sapiens	103-121	
34170488-8	2022	In human cardiomyocytes, RGZ impaired IFNgamma/TNFalpha signal transduction, blocking the phosphorylation/nuclear translocation of signal transducer and activator of transcription 1 (Stat1) and nuclear factor-kB (NF-kB), in association with a significant decrease in CXCL10 expression, IL-6 and IL-8 release.	Rosiglitazone	25-28	interleukin 6	Homo sapiens	286-290	
30488141-4	2019	Treatment with RSG ameliorated axonal injury, cell apoptosis, glia activation, and the release of inflammatory factors such as TNF-alpha, IL-1beta, and IL-6.	Rosiglitazone	15-18	interleukin 6	Homo sapiens	152-156